Navigation Links
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
Date:5/13/2008

he in-stent late loss for CUSTOM III at six-month follow-up was 0.17 mm, the in-stent binary restenosis rate was 4.4 percent, and the neointimal hyperplasia (NIH) volume was 3.8 percent.

"The CUSTOM III results are very promising and demonstrate the safety of in situ customization for treatment of simple and complex lesions. The IVUS and angiographic results confirm the efficacy of the Custom NX stent, and the Biolimus A9(R) and PLA formulation," said Bernard De Bruyne, M.D., Ph.D., of the OLV Clinic in Aalst, Belgium, and Principal Investigator for the CUSTOM III clinical trial.

"Given the complexity of the patient population from CUSTOM III, we are excited about the results, which are consistent with the outcomes observed from the CUSTOM I and CUSTOM II trials," said Gregory D. Casciaro, XTENT's President and CEO. "We continue to be pleased with the safety profile and efficacy data of Custom NX in today's real-world patients."

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6 mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6 mm segment and allows for the placement of up to 60 mm of stent. The Custom NX DES System has not been approved for sale by any regulatory authority.

CUSTOM III Webcast and Slide Presentation

As previously announced, XTENT will host a teleconference and slide presentation to review the CUSTOM III data today at 1:00 p.m. EDT (7:00 p.m. CEST). To participate in the conference call, please dial 877-591-4957 (from the U.S.) or 719-325-4895 (international). The webcast and
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
2. XTENT Announces First Quarter 2008 Financial Results
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
9. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
10. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... and LEIPZIG, Germany ... announced that it has entered into an exclusive ... development of antibody-based imaging agents to image CD4+ ... collaboration with Novotectid expands ImaginAb,s capability to precisely diagnose ... and autoimmune disease areas. The ability to image ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
(Date:9/17/2014)... 17, 2014 The global metrology services ... due to the key driving factors of increasing demands ... CAGR of 8.2 % puts the metrology services market ... 2018, as stated in a Transparency Market Research report ... Share, Growth, Trends, and Forecast 2012 – 2018”. , ...
(Date:9/17/2014)... This news release is available in Spanish . ... overweight affect more than half of the population in ... organism, one of which affects liver function. Fat accumulates ... circumstances, causes inflammation, fibrosis and finally, cirrhosis. To date, ... been hepatic biopsy. Imaging techniques such as abdominal ecography ...
(Date:9/17/2014)... (GSA) invites all journalists to attend its ... interdisciplinary conference in the field of aging from ... may register free of charge. , An estimated 4,000 ... the Walter E. Washington Convention Center and Marriott Marquis ... From Cells to Societies" and the program schedule contains ...
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Neon Sport and Fitmark have an ... industry’s most anticipated event, Joe Weider's Olympia Fitness & ... each take home a Neon Sport branded Fitmark Power ... gear. Fitmark will hold entries for the special prize ... , “There’s nothing more exciting than seeing our ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... Netherlands / Rockville, MD, USA (September 22, 2010) ... Exchange: CRX) and the Aeras Global TB Vaccine Foundation ... trial in infants of the jointly developed tuberculosis (TB) ... of the trial is to test the safety and ...
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay ... suicide rates appear to be highest among residents of ... fresh research points to a possible explanation: high altitudes. ... and the high prevalence of gun ownership, may contribute ...
... therapies against cancer to be effective, scientists need to ... makes a cancer cell resistant to a drug and ... Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center. ... , the investigators discuss how cancer cells activate a ...
... of Rhode Island Hospital, is the recipient of the ... Imaging Network (ACRIN). Dupuy received the award for leading ... (RFA) to reduce the pain of osseous metastases (cancer ... scientific paper published during the previous year that stands ...
... Physicians now have access to real time radiology ... Viewbox (patent pending) is a portable interface system ... specialist consultation to physicians using any internet-ready device. ... in transmitting patient information and offers a timely ...
Cached Medicine News:Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 2Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 3Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 4Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:Is High Altitude Linked to Suicide Risk? 2Health News:Is High Altitude Linked to Suicide Risk? 3Health News:Targeted therapy triggers complex mechanism of resistance 2Health News:Targeted therapy triggers complex mechanism of resistance 3Health News:Targeted therapy triggers complex mechanism of resistance 4Health News:Rhode Island Hospital physician receives national award for research 2Health News:Virtual Viewbox offers portable radiology access for physicians 2
... WardWatch has been designed specifically ... medical staff involved in ward rounds. ... medications and dosages, and consultations that ... (Specialist) or Registrar during Ward round ...
... is an advanced medical calculator ... Pediatric Dosing and Critical Care ... a logical complement to other ... the Daviss Drug Guide, PDR ...
... comprehensive guide provides safe, effective, ... information in a quickly accessible ... edition includes the latest drugs ... key nursing implications are highlighted ...
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
Medicine Products: